Nishanth K,Tariq E,Nzvere FP,Miqdad M,Cancarevic I. .2020 .Role of Smoking in the Pathogenesis of Multiple Sclerosis: A Review Article. Cureus, 12(8) : .
Correale J,Gaitán MI,Ysrraelit MC,Fiol MP .2017 .Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain, 10(3) : 527-46.
Howard J,Trevick S,Younger DS .2016 .Epidemiology of Multiple Sclerosis. Neurol Clin, 06(4) : 919-39.
Milo R .2019 .Therapies for multiple sclerosis targeting B cells. Croat Med, 60(2) : 87-98.
Syed YY .2018 .Ocrelizumab: A Review in Multiple Sclerosis. CNS Drugs, 32(9) : 883-90.
Ancau M,Berthele A,Hemmer B. .2019 .CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opin Biol Ther, 10(8) : 829-43.
Bigaut K,De Seze J,Collongues N. .2019 .Ocrelizumab for the treatment of multiple sclerosis. Expert Rev Neurother, 10(2) : 97-108.
Menge T,Dubey D,Warnke C,Hartung HP,Stüve O .2016 .Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother, 10(10) : 1131-9.
Myhr KM,Torkildsen Ø,Lossius A,Bø L,Holmøy T. .2019 .B cell depletion in the treatment of multiple sclerosis. Expert Opin Biol Ther, 10(3) : 261-71.
Sellebjerg F,Blinkenberg M,Sorensen PS .2020 .Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. CNS Drugs, 34(3) : 269-80.
Margoni M,Preziosa P,Filippi M,Rocca MA .2021 .Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol, : 1-19.
Hartung HP,Berger T,Bermel RA,Brochet B,Carroll WM,Holmøy T .2020 .Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord, 46 : 102492.
Bar-Or A,O'Brien SM,Sweeney ML,Fox EJ,Cohen JA. .2021 .Clinical Perspectives on the Molecular and Pharmacological Attributes of AntiCD20 Therapies for Multiple Sclerosis. CNS Drugs, 35(9) : 985-97.
Auguste P,Colquitt J,Connock M,Loveman E,Court R,Ciccarelli O .2020 .Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoecon, 38(6) : 527-36.
Gingele S,Jacobus TL,Konen FF,Hümmert MW,Sühs KW,Schwenkenbecher P .2019 .Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients. Cells, 10(1) : 12.
Chaudhuri .2012 .A. Ocrelizumab in multiple sclerosis: risks and benefits. Lancet, 6736(12) : 60508-7.
Roach CA,Cross AH,Anti-CD20 B Cell AH .2020 .Treatment for Relapsing Multiple Sclerosis. Front Neurol, 10 : 595547.
Kappos L,Li D,Calabresi PA,O'Connor P,Bar-Or A,Barkhof F .2011 .Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomized, placebo-controlled, multicentre trial. Lancet, 6736(11) : 61649-8.
Fernandez‐Diaz E,Perez‐Vicente JA,Villaverde‐Gonzalez R,Berenguer‐Ruiz L,Candeliere Merlicco A,Martinez‐Navarro ML .2021 .Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol, 8(2) : 385-94.
McCool R,Wilson K,Arber M,Fleetwood K,Toupin S,Thom H .2018 .Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord, 12 : 55-61.